

# Society of Thoracic Surgeons

Intermacs/Pedimacs  
Reporting and UG Webinar

January 27, 2021



**STS National Database™**  
Trusted. Transformed. Real-Time.

# Agenda

- Welcome and Introductions
- Call Overview
- Current Reporting Status Update
- User Feedback



Kathryn Hollifield: STS National Database Manager-Intermacs/Pedimacs

Patricia Potter: Intermacs Data Warehouse Quality Nurse

Jeanne Anne Love: Intermacs Data Warehouse, Patient Management Director and Data Quality advisor

Ryan Cantor: PhD, Statistician, Director of Reporting at the Intermacs DCC

Maceo Cleggett: Clinical Data Analyst, Intermacs Data Warehouse

Devin Koehl: Senior Clinical Analyst, Intermacs Data Warehouse

John Pennington: Intermacs Data Warehouse Senior Data Manager

Leigh Ann Jones: STS National Database Manager-CHSD/GTSD

Carole Krohn: Sr. Clinical Manager, STS National Database





Please use the Q&A Function.

We will answer as many questions as possible.

We encourage your feedback and want to hear from you!

# Current Reporting Status Update



# Outline

- Recent Report Additions - 2020 Q3
- Planned Report Additions - 2020 Q4
  - Addressing immediate requests from sites
- Longer Term Plans
  - How to consolidate reporting that still meets sites needs



# Recent Report Additions - 2020 Q3 – Recent Year (4 Quarters) -> Recent (6 Quarters)

- The recent report was updated to include a rolling 6 quarters of data
- Using a rolling 4 quarters meant few patient at risk at 12m and for most centers a 1 year survival estimate was not possible
- Rolling 6 quarters facilitates the estimation of 1 year survival


STS Quality Assurance Quarterly Report (2020 Q3) - Recent

107

COVERAGE: April 1, 2019 - September 30, 2020 - Patients with Primary VAD

SITE: Hospital X - (Random 100 Patients)

Exhibit 35. Post Implant Survival - PRIMARY OVERALL



Months after Device Implant	STS Intermacs	HOSPX-9999
1	94.4% (94.1%-94.8%)	91.8% (88.5%-94.2%)
3	90.2% (89.7%-90.7%)	89.5% (85.9%-92.3%)
6	87.5% (86.9%-88.0%)	86.9% (82.8%-90.0%)
9	86.0% (85.4%-86.6%)	86.9% (82.8%-90.0%)
12	84.8% (84.0%-85.3%)	86.9% (82.8%-90.0%)




# Recent Report Additions - 2020 Q3 – Patient Profile

- ***Kaplan Meier – Survival on a Device By Patient Profile Added to All Reports***
  - ***Exhibit 45a. Post Implant Survival: Patient Profile 1 - Critical Cardiogenic Shock***
  - ***Exhibit 45b. Post Implant Survival: Patient Profile 2 - Progressive Decline***
  - ***Exhibit 45c. Post Implant Survival: Patient Profile 3 - Stable but Inotrope Dependent***
  - ***Exhibit 45d. Post Implant Survival: Patient Profile 4+ Resting Symptoms and Less Sick***






**Post Implant Survival: Patient Profile 1 - Critical Cardiogenic Shock**  
 Primary Prospective Implants: June 23, 2006 to September 30, 2020



Note: These results reflect unadjusted survival estimates. Observed differences may be due to patient selection, device selection, clinical care and/or other factors.  
 p (log-rank) = 0.5387  
 Event: Death (censored at transplant or cessation of support)  
 Shaded areas indicate 70% confidence limits



**Post Implant Survival: Patient Profile 2 - Progressive Decline**  
 Primary Prospective Implants: June 23, 2006 to September 30, 2020



Note: These results reflect unadjusted survival estimates. Observed differences may be due to patient selection, device selection, clinical care and/or other factors.  
 p (log-rank) = 0.9725  
 Event: Death (censored at transplant or cessation of support)  
 Shaded areas indicate 70% confidence limits




Your Site vs Intermacs  
 For Patient profile 1,2,3,4+

Available for:

- Cumulative – Primary VAD Patients
- Cumulative – Prior VAD Patients
- Recent – Primary VAD Patients
- Recent – Prior VAD Patients

Tables with estimates at specific time points


**Post Implant Survival: Patient Profile 3 - Stable but Inotrope Dependent**  
 Primary Prospective Implants: June 23, 2006 to September 30, 2020



Note: These results reflect unadjusted survival estimates. Observed differences may be due to patient selection, device selection, clinical care and/or other factors.  
 p (log-rank) = 0.8776  
 Event: Death (censored at transplant or cessation of support)  
 Shaded areas indicate 70% confidence limits



**Post Implant Survival: Patient Profile 4+ - Resting Symptoms and Less Sick**  
 Primary Prospective Implants: June 23, 2006 to September 30, 2020



Note: These results reflect unadjusted survival estimates. Observed differences may be due to patient selection, device selection, clinical care and/or other factors.  
 p (log-rank) = 0.0974  
 Event: Death (censored at transplant or cessation of support)  
 Shaded areas indicate 70% confidence limits



# Planned Report Additions - 2020 Q4

- Many requests for reports that include ALL centers patients
- Expand the set of reports to include:
  - Comprehensive – (all patients across all time)
  - Comprehensive – Recent (all patients within the last 6 quarters)



# Planned Report Additions - 2020 Q4

- Add implant year to Exhibit 49: Patients Implanted at your Center but Excluded from this Analysis
  - Help track patients inclusions



# Planned Report Additions - 2020 Q4

- Adjustment to Death on a Device reporting
  - Currently patients are censored at cessation of support (explant or turned off for any reason)
  - Censored = unobserved event
  - Some cessation of support is actually withdraw of support
  - Update
  - Patients with cessation of support but have a reported death date on the same or next day -> reported as death on a device for both Kaplan-Meier Survival and Competing outcomes



# Planned Report Additions - 2020 Q4

- Mirror v6.0 data collection changes
  - Vast majority of exhibit will stay the same
  - Comorbidity exhibits will match the new version (data has been mapped to the new values where ever possible)
    - Most items will be comparable
    - Some components will be removed from the reports if they no longer reflected the data collection



# Note: WinZip -> 7-Zip

- Starting new quarter we will be using 7zip instead of WinZip to prepare QA zip packets and site dataset packets, this change was mandated by UAB IT
- We've tested and don't anticipate issues
- But if any issues are experienced let us know



# Longer Term Plans for Report Design Process

- Currently
  - STS leadership and DCC assesses requests ad hoc
  - try to incorporate ALL request, as soon a possible
  - Only additions of content
  - pro – A LOT of great information
  - con – Too much information? Which measures are the best to use? How to best consolidate into a core set of comparisons?
- Ideally
  - Continual collection of report edit ideas
  - Annual Edits, Review and Approved by STS Leadership, Targeted for Benchmarking
  - Outcome Analytic Tool (under construction) may take the place of some of the detailed comparison in the current report collection
- We need feedback
  - What exhibits are most helpful
  - Ideas on new information and how to represent the data that will be useful to your site
  - Items that can be removed
- As new reports are developed, this webinar forum can provide useful discussion / feedback



# Intermacros & Pedimacs Resources:

<https://www.uab.edu/medicine/intermacros/intermacros-documents>

[www.sts.org](http://www.sts.org)

[Intermacrosfaq@sts.org](mailto:Intermacrosfaq@sts.org)





# Thank you for joining!

Next Intermacs/Pedimacs Webinars

User Group Webinar: February 24, 2021 @ 1 pm CT

Reporting Webinar: April 15, 2021 @ 2 pm CT



**STS National Database**<sup>™</sup>  
Trusted. Transformed. Real-Time.